PARP Inhibitor Possible Addition to Pancreatic Cancer Treatment Regimen
the Cancer Therapy Advisor take:
Of all the solid tumors, locally advanced pancreatic cancer has the lowest 5-year survival rate, at 4%. Since tumors usually involve vital blood vessels, patients with this disease are seldom candidates for surgery.
Although standard treatment is currently chemotherapy and radiotherapy given concurrently, there have been no significant survival improvements from any treatment. According to a study published in Translational Oncology, researchers are in the process of developing a multistep treatment for locally advanced pancreatic cancer.
First author Richard Tuli, MD, PhD, and researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute created an investigational regimen and are attempting to identify biomarkers for the disease. After a successful study using animal models, the researchers found a combination of radiotherapy, chemotherapy, and a drug using a PARP inhibitor that extended survival in mice. After chemotherapy and radiation therapy damage tumor DNA, proteins called PARPs begin repairing the damaged DNA, which causes tumor cells to regrow.
Thus, researchers added a PARP inhibitor to the treatment regimen. In addition, researchers found that patients with BRCA1 and/or BRCA2 mutations would be most likely to benefit from PARP inhibitors. A clinical trial is currently enrolling eligible patients as the next step to determine whether this regimen is effective in humans.
Investigators are developing a novel, multistep investigational treatment for pancreatic cancer.
Locally advanced pancreatic cancer has the lowest survival rate of any solid tumor, with a cumulative five-year survival rate of only 4 percent for all stages of disease. Surgery is rarely an option for patients because tumors often involve vital blood vessels. Chemotherapy and radiotherapy given concurrently remain the mainstay treatment, yet to-date, no treatment has had a significant impact on improving outcomes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer